PURPOSE: The aim of our study was to investigate the occurrence of fluorodeoxyglucose (FDG) avidity in draining axillary lymph nodes after vaccination against influenza (H1N1v pandemic and seasonal) and to determine the period of increased FDG uptake. METHODS: During December 2009, patients referred for (18)F-FDG positron emission tomography (PET)/CT scans (n = 293) filled in a questionnaire concerning vaccination type (seasonal and/or H1N1v), time and anatomical localization of vaccination. Only injections in deltoid regions were evaluated, thus ensuring that draining lymph nodes were axillary. If more vaccinations had been given, only the latest vaccination was evaluated in each deltoid region. RESULTS: Of all patients who underwent PET/CT scans during December 2009, 26% had been vaccinated with at least one influenza vaccination in the deltoid region. A total of 92 'draining' and 60 'reference' (i.e. contralateral, non-vaccinated) axillary lymph nodes were evaluated in 61 patients (19 of 61 patients were scanned twice). The maximal intensity in FDG uptake (SUV(max)) in draining lymph nodes was 5 g/ml body weight (BW), whereas the maximal intensity in reference lymph nodes was 1.9 g/ml BW. The SUV(max) was normalized approximately 40 days after vaccination. No significant enlargement of metabolically active draining lymph nodes could be demonstrated on CT scan. Chemotherapy or immunosuppressive drugs given within 2 weeks from vaccination did not affect SUV(max) in the axillary lymph nodes. CONCLUSION: Influenza vaccination may lead to FDG-avid draining lymph nodes beyond 1 month.
PURPOSE: The aim of our study was to investigate the occurrence of fluorodeoxyglucose (FDG) avidity in draining axillary lymph nodes after vaccination against influenza (H1N1v pandemic and seasonal) and to determine the period of increased FDG uptake. METHODS: During December 2009, patients referred for (18)F-FDG positron emission tomography (PET)/CT scans (n = 293) filled in a questionnaire concerning vaccination type (seasonal and/or H1N1v), time and anatomical localization of vaccination. Only injections in deltoid regions were evaluated, thus ensuring that draining lymph nodes were axillary. If more vaccinations had been given, only the latest vaccination was evaluated in each deltoid region. RESULTS: Of all patients who underwent PET/CT scans during December 2009, 26% had been vaccinated with at least one influenza vaccination in the deltoid region. A total of 92 'draining' and 60 'reference' (i.e. contralateral, non-vaccinated) axillary lymph nodes were evaluated in 61 patients (19 of 61 patients were scanned twice). The maximal intensity in FDG uptake (SUV(max)) in draining lymph nodes was 5 g/ml body weight (BW), whereas the maximal intensity in reference lymph nodes was 1.9 g/ml BW. The SUV(max) was normalized approximately 40 days after vaccination. No significant enlargement of metabolically active draining lymph nodes could be demonstrated on CT scan. Chemotherapy or immunosuppressive drugs given within 2 weeks from vaccination did not affect SUV(max) in the axillary lymph nodes. CONCLUSION: Influenza vaccination may lead to FDG-avid draining lymph nodes beyond 1 month.
Authors: Daniele Focosi; Francesco Caracciolo; Sara Galimberti; Federico Papineschi; Mario Petrini Journal: Ann Hematol Date: 2007-12-18 Impact factor: 3.673
Authors: Sujatha Iyengar; Bennett Chin; Joseph B Margolick; Beulah P Sabundayo; David H Schwartz Journal: Lancet Date: 2003-09-20 Impact factor: 79.321
Authors: Anders Thomassen; Anne Lerberg Nielsen; Jeppe Kiilerich Lauridsen; Björn Alexander Blomberg; Søren Hess; Henrik Petersen; Allan Johansen; Jon Thor Asmussen; Jesper Roed Sørensen; Jørgen Johansen; Christian Godballe; Poul Flemming Høilund-Carlsen Journal: Am J Nucl Med Mol Imaging Date: 2014-03-20
Authors: Simone M Goldinger; Reinhard Dummer; Petra Baumgaertner; Daniela Mihic-Probst; Katrin Schwarz; Anya Hammann-Haenni; Joerg Willers; Christine Geldhof; John O Prior; Thomas M Kündig; Olivier Michielin; Martin F Bachmann; Daniel E Speiser Journal: Eur J Immunol Date: 2012-08-28 Impact factor: 5.532
Authors: Zarni Win; January Weiner Rd; Allan Listanco; Neva Patel; Rohini Sharma; Aldona Greenwood; Jeroen Maertzdorf; Hans-Joachim Mollenkopf; Kat Pizzoferro; Thomas Cole; Caroline L Bodinham; Stefan H E Kaufmann; Philippe Denoel; Giuseppe Del Giudice; David J M Lewis Journal: Front Immunol Date: 2021-02-05 Impact factor: 7.561